Home » Topics » BioWorld Science, Hematologic

BioWorld Science, Hematologic
RSS

New lower dose of rivaroxaban approved by FDA

Oct. 31, 2017

European Commission approves new indication for Firazyr

Oct. 27, 2017

FDA gives breakthrough therapy designation to valoctocogene roxaparvovec

Oct. 27, 2017

Ergomed reports phase II topline results for first-in-class hemostat PeproStat

Oct. 23, 2017

Health Canada gives priority review status to ProMetic's NDS for Ryplazim

Oct. 20, 2017

Acticor Biotech reaches agreement on phase I study of ACT-107

Oct. 18, 2017

Bayer submits marketing authorization application for BAY-94-9027 in Japan

Oct. 18, 2017

FDA accepts ProMetic's BLA for Ryplazim

Oct. 16, 2017

EMA accepts Cinfa's MAA for biosimilar pegfilgrastim B-12019

Oct. 6, 2017

FDA accepts IND for gene-edited cell therapy for beta-thalassemia

Oct. 5, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...